CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
NRG-GY003 NRG Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian; Primary Peritoneal or Fallopian Tube Cancer Adult CIRB - Early Phase Emphasis
NRG-GY004 NRG Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian; Fallopian Tube; or Primary Peritoneal Cancer Adult CIRB - Late Phase Emphasis
NRG-GY005 NRG A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone; or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian; fallopian tube; or primary peritoneal cancer (COCOS) Adult CIRB - Late Phase Emphasis
NRG-GY006 NRG A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2; Stage II; IIIB; or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer Adult CIRB - Late Phase Emphasis
NRG-GY007 NRG A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian; Fallopian Tube; or Primary Peritoneal Cancer Adult CIRB - Late Phase Emphasis
NRG-GY008 NRG A Phase II Evaluation of Copanlisib (BAY 80-6946); (IND #130822); A Selective Inhibitor of PI3KCA; in Patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations Adult CIRB - Late Phase Emphasis
NRG-GY009 NRG A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab (IND #134427) versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer Adult CIRB - Late Phase Emphasis
NRG-GY011 NRG A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus Adult CIRB - Late Phase Emphasis
NRG-GY012 NRG A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer Adult CIRB - Late Phase Emphasis
NRG-GY014 NRG A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma Adult CIRB - Late Phase Emphasis